Stoke Therapeutics, Inc. (NASDAQ:STOK) to Post Q2 2024 Earnings of ($0.43) Per Share, Leerink Partnrs Forecasts

by · The Cerbat Gem

Stoke Therapeutics, Inc. (NASDAQ:STOK – Free Report) – Analysts at Leerink Partnrs issued their Q2 2024 earnings per share (EPS) estimates for Stoke Therapeutics in a research note issued to investors on Tuesday, April 9th. Leerink Partnrs analyst R. Li forecasts that the company will post earnings per share of ($0.43) for the quarter. The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.28) per share. Leerink Partnrs also issued estimates for Stoke Therapeutics’ Q3 2024 earnings at ($0.48) EPS, FY2027 earnings at ($1.90) EPS and FY2028 earnings at ($0.05) EPS.

A number of other brokerages have also recently commented on STOK. Canaccord Genuity Group upped their price target on Stoke Therapeutics from $18.00 to $21.00 and gave the company a “buy” rating in a research note on Tuesday, March 26th. Needham & Company LLC reiterated a “buy” rating and issued a $22.00 price objective on shares of Stoke Therapeutics in a research report on Thursday. HC Wainwright reiterated a “buy” rating and issued a $35.00 price objective on shares of Stoke Therapeutics in a research report on Tuesday, March 26th. TD Cowen upgraded Stoke Therapeutics from a “market perform” rating to an “outperform” rating in a research report on Tuesday, March 26th. Finally, JPMorgan Chase & Co. boosted their price objective on Stoke Therapeutics from $6.00 to $13.00 and gave the company a “neutral” rating in a research report on Tuesday, March 26th. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $19.63.

Get Our Latest Analysis on Stoke Therapeutics

Stoke Therapeutics Trading Down 5.4 %

Shares of NASDAQ:STOK opened at $12.77 on Friday. The stock has a market capitalization of $591.25 million, a P/E ratio of -5.39 and a beta of 0.77. Stoke Therapeutics has a 1-year low of $3.35 and a 1-year high of $16.40. The business has a 50-day moving average price of $8.01 and a two-hundred day moving average price of $5.72.

Insiders Place Their Bets

In other Stoke Therapeutics news, insider Barry Ticho sold 10,000 shares of the stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $4.80, for a total transaction of $48,000.00. Following the transaction, the insider now owns 6,981 shares in the company, valued at approximately $33,508.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, insider Barry Ticho sold 10,000 shares of the firm’s stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $4.80, for a total value of $48,000.00. Following the transaction, the insider now owns 6,981 shares in the company, valued at $33,508.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Edward M. Md Kaye sold 11,150 shares of the firm’s stock in a transaction on Tuesday, March 19th. The stock was sold at an average price of $6.10, for a total value of $68,015.00. Following the completion of the transaction, the chief executive officer now owns 69,350 shares in the company, valued at approximately $423,035. The disclosure for this sale can be found here. Insiders have sold 32,741 shares of company stock worth $223,115 in the last 90 days. Company insiders own 12.30% of the company’s stock.

Institutional Trading of Stoke Therapeutics

Several large investors have recently bought and sold shares of STOK. GSA Capital Partners LLP raised its position in shares of Stoke Therapeutics by 514.7% during the third quarter. GSA Capital Partners LLP now owns 348,069 shares of the company’s stock worth $1,371,000 after acquiring an additional 291,443 shares during the last quarter. Trexquant Investment LP raised its position in shares of Stoke Therapeutics by 166.9% during the third quarter. Trexquant Investment LP now owns 127,581 shares of the company’s stock worth $503,000 after acquiring an additional 79,785 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Stoke Therapeutics by 9.3% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 146,076 shares of the company’s stock worth $576,000 after acquiring an additional 12,478 shares during the last quarter. Corton Capital Inc. bought a new position in shares of Stoke Therapeutics during the third quarter worth about $58,000. Finally, Public Employees Retirement System of Ohio bought a new position in shares of Stoke Therapeutics during the third quarter worth about $64,000.

Stoke Therapeutics Company Profile

(Get Free Report)

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.

Further Reading